The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

The graft versus host disease market is experiencing significant growth, driven by the ongoing adoption of branded therapies such as JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK compared to off-label ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...

Gilead Sciences to pay $35 million upfront in AI drug discovery deal with Stanford University spinout backed by Nvidia and ...

For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place where researchers have developed new therapies in-house and published ...

Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED) NVIDIA’s push into the life sciences sector has been rewarded by a wide-ranging deal with Roche’s ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

(KRON) — Biotech firm Genentech is laying off nearly 100 employees at its South San Francisco headquarters, according to a ...

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults. The treatment, called Tecentriq Hybreza, can ...

Genentech, a drugmaker based in South San Francisco, is laying off 93 more local workers just months after a 436-worker cut. The company, which is owned by Swiss pharmaceutical giant Roche ...

Runimotamab is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate ...